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Background: Cervical cancer is one of the most common cancers affecting women worldwide. It is well established
that human papilloma virus (HPV) infection is the prime risk factor in the development of cervical cancer. The current
screening and diagnostic tests have limitations in identifying the range of lesions caused by HPV. The current study aims
to evaluate the diagnostic value of p16 immunohistochemical (IHC) investigation in high-risk human papillomavirus
(HR-HPV) related lesions of the uterine cervix in Hospital Tuanku Jaafar, Seremban, Malaysia.
Methods: A total of 75 cases were selected from the records of Pathology services, Hospital Tuanku Ja’afar, Seremban.
The samples were collected in three separate groups (n = 25 per group) as Carcinoma cervix, Carcinoma in situ and
Chronic cervicitis. The demographic data of the patients and the representative paraffin blocks were retrieved from
Hospital Tuanku Ja’afar, Seremban. The immunohistochemical staining with p16 and HPV 16 L1 were done on all cases.
The staining intensity and density were observed and compared among the three groups of cases.
Results: Immunohistochemistry of p16INK4A staining shows nil (0/25) expression in the cervicitis patients, 72%
(18/25) in CIN patients and 100% (25/25) in cervical carcinoma. HPV 16 L1 was positive in 100% (25/25) of cervicitis
patients, 96% (24/25) of CIN patients and 40% (10/25) of cervical cancers patients. A chi square test was used to analyze
the result and the obtained p value was <0.05.
Conclusion: p16 expression was strongly observed in cervical cancer and minimally observed in cervicitis. Thus
indicating p16 immunohistochemistry investigations can aid in diagnosing the different categories of cervical lesions
into benign, insitu and malignant.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_202
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Cervical cancer is the third most commonly diagnosed
cancer and the fourth leading cause of cancer death in fe-
males worldwide, accounting for 9% (529,800) of the total
new cancer cases [1]. Despite the implementation of Pap
test that has successfully brought dramatic reduction in
the incidence and mortality worldwide caused by cervical
cancer from 50% to 75% [2], there are still a substantial
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article, unless otherwise stated.adequately screened [3], proving diagnostic limitation of
the Pap test. It is also estimated that false negative rate for
the Pap test for cervical premalignant lesions and cervical
cancer lies between 15% to 50% [4] and the false positive
rate of approximately 30% [4].
Conversely, conditions such as reserve cell hyperplasia,
inflammatory atypia and atypia squamous metaplasia
often give rise to significant amount of false positive test
result of the Pap test. This leads the patients to repeat
the test, or look into unnecessary and more invasive
diagnostic procedure to reconfirm the result of the ini-
tial positive Pap test and also possibility of overtreat-
ment. Due to the limitation of the current screeningtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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well as high positive predictive value (PPV) and also nega-
tive predictive value (NPV) to improve cervical cancer
screening programs and especially to accurately diagnose
precancerous lesions are increasing [5,6]. Therefore, it is
proposed that histology assessment plays an important
role in diagnosing precancerous lesions and also invasive
squamous cell carcinoma of the cervix (SCC) [7], but
there could be intra-observer and inter-observer diagnos-
tic discrepancies even among panel of pathologist review-
ing the slides [8]. Hence to further improve the accuracy
of screening test, various IHC biomarkers have been eval-
uated for its sensitivity and specificity of staining towards
precancerous lesions and uterine cervical carcinoma in
histological biopsy.
Epidemiological and molecular studies have shown
that human papilloma virus (HPV) is the most import-
ant etiological agent for cervical carcinogenesis. In cer-
vical lesions, overexpression of p16 is observed and it is
thought to be resulted from the increasing level of E2F
transcription factor which is releases from pRB after
binding to HPV E7 oncoprotein [9].
The association of p16 and HR-HPV in Asia and in
more particular Malaysia are still relatively unexplored.
This study aims to evaluate the diagnostic value of p16
IHC in differentiating the different categories of HR
HPV infected cervical lesions [10].
Methods
Research sample
The biopsies referred for histological evaluation of
Cervical lesions were studied retrospectively from January
2012 to December 2012, at department of pathology,
Hospital Tuanku Ja’afar, Seremban. The study was ap-
proved by the International Medical University joint com-
mittee for ethics and research. A total of 75 cases were
selected from the records of Pathology services, Hospital
Tuanku Ja’afar, Seremban. The samples (n = 25 per group)
were collected as the following groups:
Group 1 – Twenty five (25) cases of Carcinoma cervix
Group 2 - Twenty five (25) cases of Carcinoma in situ
Group 3 – Twenty five (25) cases of Chronic cervicitis
After obtaining the consent from the relevant author-
ities of Hospital Tuanku Ja’afar, Seremban, a representa-
tive paraffin block of each case along with the patient
demographic data were retrieved from Department of
Pathology, Hospital Tuanku Ja’afar, Seremban.
All the 75 cases were submitted for IHC with p16
antibody {Mouse monoclonal [2S9A12] to CDKN2A/
p16INK4a, Abcam ab 54210} and HPV 16 L1 antibody
{Mouse monoclonal [CamVir 1] to HPV 16 L1, Abcam
ab 69}.The IHC methods done in this study followed a standard
protocol by the manufacturers with needed optimization.
Two pathologists screened the IHC slides independently.
A positive and a negative control were run with every
batch of IHC staining done. A positive reaction was con-
sidered if staining of cells of interest for the antibody in
question is observed. The Allred scoring system [11] for
IHC staining of the cervical tissue was implemented to
allow qualitative and semi-quantitative analysis on the
IHC stained slides. The two parameters of interest were
staining intensity (SI) and staining density (SD).
Staining intensity (SI) was scored according to the
following scale:
no visible staining = 0, weak staining = 1+, moderate
staining = 2+, and intense staining = 3 + .
Staining density (SD) for each antibody was semi-
quantified into five main categories based on the per-
centage of cells being stained positive: 0 = no cells stained
positive, 1 = <10% of the cells stained positive, 2 = 10-50%
stained positive, 3 = 50-90% stained positive and 4= > 90%
of the cells stained positive. The respective grades given to
both SI and SD were tabulated and averaged.
Results
Age and racial prevalence
Ages of the patients from the 3 groups of cases (cervicitis,
CIN, and cervical cancer) ranged from 21 years to 85 years
with a mean of age 49.2 years. Patient with cervical cancer
(mean age of 58.9 years) was older compared to CIN pa-
tients (mean age of 43.4 years). Cervicitis patients were
relatively younger with the mean age of 39.7 years.
Overall, Indians stands the largest proportion of 37%
(28/75 cases) of having cervical lesions followed very
closely by the Malays 36% (27/75 cases) and Chinese
23% (17/75 cases). 4% of the patients are of race other
than the 3 main races belonging to Malaysia as shown in
the Figure 1.
In the cervicitis group, the Indians (13 cases, 52%)
were more commonly affected followed closely by the
Malays (8 cases, 32%), and the Chinese (4 cases, 16%).
As for the carcinoma-in-situ group of patients, more
Malays (10 cases, 40%) were affected than the other
races. In the cervical cancer group Malays (9 cases, 36%)
were more commonly affected.
Immunohistochemical staining for p16 and HPV
16 L1 was done for all 75 cases (100%). Figure 2 shows
the p16 IHC staining intensity scores of 0, 1, 2 & 3 la-
belled as A, B, C & D respectively. Of the 25 cases in the
cervicitis group, none of the cases showed p16 expres-
sion. Whereas 72% (18/25 cases) of the CIN cases
showed p16 positivity and all the cervical cancer cases
(100%) showed positivity as shown in the Figure 3. This
means that, p16 expression is seen more in cancer group
in comparison to in-situ and cervicitis group.
Figure 1 Showing overall racial prevalence of the sample cohort.
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positive in all the cervicitis cases ( 100.0%), 24 cases
(96.0%) of carcinoma in situ and 10 cases (40.0%) of cer-
vical cancer as shown in the Figure 3.
The Allred scoring system for IHC staining was imple-
mented and the mean intensity and mean density score
for each IHC marker were calculated and tabulate in theFigure 2 Showing immunohistochemical staining intensity scores of pTable 1. It was observed that HPV 16 L1 had the higher
mean intensity score with a score of 1.75 and followed
by the p16 with a score of 1.07. Besides that, HPV 16 L1
also had the higher mean density score of 3.16 compared
to the p16 with a mean density score of only 1.76.
As the disease status progress from the cervicitis to-
wards the cervical cancer group, it can be seen that the
mean intensity score increases from 0.00 (cervicitis),
1.04 (CIN) and lastly to 2.16 (cervical cancer).
Meanwhile, the p16 mean density score also followed
the pattern of increase as p16 intensity. The mean dens-
ity of cell stained increases from 0.4 (cervicitis), 1.6
(CIN) and lastly 3.68 (cervical cancer).
On the other hand, the HPV 16 L1 mean staining in-
tensity showed inversed relationship as compared to
those seen in p16 marker. The mean score decreases
from 2.32 (cervicitis), CIN (2.12) and 0.84 for cervical
carcinoma. The HPV 16 L1 mean density score also ob-
served the same decrease from 3.68 (CIN) to cervical
carcinoma (1.8).
The tabulated p16 expression and the disease categor-
ies was ran onto statistical test using SPSS version 18
and the chi square test was calculated and the p value
was <0.05.
Discussion
P16INK4A is a gene that is expressed by host cells in re-
sponse to HPV infection, and is not normally expressed16. A-Score 0, B-Score 1, C-Score 2, D-Score 4.
Figure 3 Showing p16 and HPV 16 L1 positivity.
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chromosome 9p21-22, and maps for a cyclin dependent
kinase (cdk)-4 inhibitor. It normally decelerates the cell
cycle at the G1-S phase checkpoint by inhibiting the cdk
that phosphorylates and inactivates pRb. It is specifically
binds to cyclin D-cdk4/6 complex, and thereby prevents
the conformational change activated by phosphorylation
of pRb that will release transcription factor E2F from the
E2F/pRb complex, and so causes a halt at the checkpoint
before entering into the S1 phase [13].
Upon functional inactivation of pRb by E7 oncogene,
there is increased activity of cyclin dependent kinases that
propel the cell into the S phase of cell cycle. As p16 ex-
pression is involved in a negative feedback or a down
regulator of cell proliferation but this inhibitory function
is proved to be ineffective in the context of high risk HPV
integrated infection due to the substantially high amount
of E6 and E7 oncogene present in the infected host cells.
Therefore it is a sensitive surrogate marker for such HPV
infections, specifically for integration of viral E6 and E7
into squamous epithelial cell genome.
Only the high risk HPV subtypes have the ability to inte-
grate into the replicating basal and parabasal epithelial
stem cell genome resulting in overexpression of p16INK4A
protein from the basal layers up, and perhaps reflecting
malignant transformation. As a result, the p16INK4A
staining pattern for the high risk HPV subtypes is those of
strong, diffuse staining of both nuclei and cytoplasm [14].Table 1 Showing mean intensity and density scores of
the p16 & HPPV 16 IHC






p16 43( 57.3) 1.07 1.76
HPV 16 L1 64 (85.3) 1.75 3.16In contrasts, the immunostaining pattern associated with
episomal infection by low risk HPV subtypes displayed
weak, focal staining of nuclei and cytoplasm in the inter-
mediate and superficial layers only.
In addition, p16INK4A is not only expressed in cervical
tissue but also in normal tissues. In adults, p16INK4A is
found in normal proliferative endometrium, oesophageal
squamous epithelium, breast ductal epithelium, antral gas-
tric glands, salivary glands, Langerhans cells in pancreas,
anterior pituitary, Sertoli and Leydig cells in testis. Whereas
in infants, p16INK4A expression is limited to thymic cor-
puscles and only rarely in pancreatic epithelial cells [15].
The other Biomarkers have been used to evaluate the
cervical neoplastic lesions. Yanxia et al showed the down
regulation of miR-143 was a promoting factor for the oc-
currence of cervical SCC, and related to the infection of
HPV16. The down regulation of miR-143 was also re-
lated with tumor size and lymph node metastasis [16].
Hongxiu et al showed that D2-40 may be a helpful
marker for distinguishing CIN1 from CIN2/3 in patho-
logical practice [17]. Hongqian et al showed the Potential
clinical usefulness of the hTERC FISH in distinguishing
patients with clinically significant cervical lesions from
those that are insignificant lesions, especially in HPV-
infection patients [18].
Based on studies published so far, p16 could be poten-
tially be utilized in the detection of HR-HPV in Pap
smears. Many reports have described the successful appli-
cation of p16 immunohistochemistry (IHC) to liquid based
and conventional Pap smears, with good concordance be-
tween p16 and Pap smear results [19]. Ekalaksanan et al
[20], stated that all cases of HSIL and squamous carcinoma
in his research showed p16 positive by IHC. Similar results
were obtained by Klaes et al [12]. Some studies have also
suggested the utility of p16 IHC in the interpretation and
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grade squamous intraepithelial lesions (LSIL) [21]. Cer-
vical intraepithelial neoplasia (CIN1) with diffuse p16
staining has a greater risk of progression to HSIL over p16
negative cases [22]. A possible reason for the lower ex-
pression of p16INK4A in low grade lesions may be be-
cause a certain percentage is thought to be caused by low
risk HPV types. This is because the affinity of the E7 pro-
tein of low risk HPV for pRb is much lower than that of
high risk HPV types, there would not be any overexpres-
sion of p16INK4A [23].
The study done by Iana et al concluded that in large
numbers of sections we were able to prove that immuno-
histochemical detection p16INK4a expression can be used
as a specific diagnostic marker of all degrees of cervical
dysplasia and cervical cancer, and possibly as a surrogate
marker for HPV infection, due to the relationship between
p16INK4A and HPV E7 inactivated RB protein [24].
Benvolo et al has stated that, in this context, p16 test-
ing can substantially improve the conventional morpho-
logical diagnosis of cervical preneoplastic lesions [25].
Nevertheless only a few literatures have analyzed the
correlation between p16 overexpression and HPV infec-
tion [25]. However, morphological criteria alone are not
sufficient to distinguish lesions that may regress from
those that might progress and persists. Therefore, the
evaluation of HR-HPV infection as well as p16 immu-
noreactivity, could be useful tools of particular clinical
value in identifying cases with a higher possibility to pro-
gress to high grade lesions. In a study done by Maria et
al study, they managed to show a statistically significant
inter-relationship occurring between p16 overexpression
and HR-HPV infection with a 84% sensitivity, 98% speci-
ficity, 97% PPV, 86% NPV [25].
All these literatures proved that p16 seems likely to be
superior to other methods of HR-HPV detection because
it can assess gene expression and not merely due to the
presence of virus. Therefore, p16INK4A immunostaining
may play a useful role in classifying the different groups
of lesions.Conclusion
The study showed a significant statistical difference in the
expression of p16 between the low grade and high grade
cervix lesions. P16 immunohistochemistry can be used as
a useful diagnostic tool for detecting high grade cervical
lesions.
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